Literature DB >> 3721064

Retinopathy in older type II diabetics. Association with glucose control.

D M Nathan, D E Singer, J E Godine, C H Harrington, L C Perlmuter.   

Abstract

Non-insulin-dependent (type II) diabetics over the age of 55 comprise most of the diabetic population and are at considerable risk for the development of both macrovascular and microvascular complications. We studied the prevalence of retinopathy and its association with putative risk factors for its development in an elderly (55- to 75-yr-old) population of type II diabetics. Our cross-sectional analysis revealed that duration of diabetes and hemoglobin A1c (HbA1c) concentration were the two major predictors of the presence of retinopathy. Duration effect was seen after 10 yr of diabetes, whereas HbA1c effect was linear over its entire range. Hypertension, which has been reported to be a risk factor for microvascular disease in younger diabetic patients, was not associated with retinopathy in the older type II population. Multiple logistic regression analysis revealed that both the duration of diabetes and HbA1c remained significant independent determinants of retinopathy even after taking age and blood pressure into account. Our results support an etiologic role for metabolic control in the development of retinopathy in the elderly type II population.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3721064     DOI: 10.2337/diab.35.7.797

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

1.  Prevalence of diabetic retinopathy in patients with diabetes mellitus diagnosed after the age of 70 years.

Authors:  M Cahill; A Halley; M Codd; N O'Meara; R Firth; D Mooney; R W Acheson
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

Review 2.  Glycemic control and complications of diabetes mellitus.

Authors:  I B Hirsch
Journal:  West J Med       Date:  1995-05

3.  Effects of very mild versus overt diabetes on vascular haemodynamics and barrier function in rats.

Authors:  G Pugliese; R G Tilton; A Speedy; K Chang; E Santarelli; M A Province; D Eades; W R Sherman; J R Williamson
Journal:  Diabetologia       Date:  1989-12       Impact factor: 10.122

4.  Hyperinsulinemia in hypertension: increased secretion, reduced clearance or both?

Authors:  D Giugliano; A Quatraro; A Minei; N De Rosa; L Coppola; F D'Onofrio
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

5.  Neovascular glaucoma at king khaled eye specialist hospital - etiologic considerations.

Authors:  Hanan N Al-Shamsi; David K Dueker; Sawsan R Nowilaty; Sami A Al-Shahwan
Journal:  Middle East Afr J Ophthalmol       Date:  2009-01

Review 6.  Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  B H Wolffenbuttel; T W van Haeften
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

7.  Glycated haemoglobin, plasma glucose and diabetic retinopathy: cross-sectional and prospective analyses.

Authors:  Q Z Liu; D J Pettitt; R L Hanson; M A Charles; R Klein; P H Bennett; W C Knowler
Journal:  Diabetologia       Date:  1993-05       Impact factor: 10.122

Review 8.  Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.

Authors:  J W Steele; D Faulds; K L Goa
Journal:  Drugs Aging       Date:  1993 Nov-Dec       Impact factor: 3.923

9.  Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients.

Authors:  Sydney E S Brown; David O Meltzer; Marshall H Chin; Elbert S Huang
Journal:  J Am Geriatr Soc       Date:  2008-05-19       Impact factor: 5.562

10.  Health care resource utilization associated with a diabetes center and a general medicine clinic.

Authors:  Elbert S Huang; Suzanne Gleason; Ronald Gaudette; Enrico Cagliero; Patricia Murphy-Sheehy; David M Nathan; Daniel E Singer; James B Meigs
Journal:  J Gen Intern Med       Date:  2004-01       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.